CTNM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Contineum Therapeutics Inc (CTNM) is not a strong buy for a beginner, long-term investor at this time. The lack of significant positive catalysts, insider selling, and a recent downgrade from analysts suggest limited near-term upside. Additionally, the company's financial performance and technical indicators do not indicate a compelling entry point.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), but the MACD is negatively expanding (-0.0433), and RSI is neutral at 61.81. The price is near resistance levels (R1: 16.127, current price: 16.085), suggesting limited immediate upside.
NULL identified. No recent news or significant positive developments. The stock has bullish moving averages, but other indicators are neutral or negative.
Morgan Stanley downgraded the stock with a reduced price target of $14, citing disappointing Phase 2 study results and delayed Phase 3 trials. Insider selling has increased significantly (523.19% over the last month). Hedge funds are neutral, and there are no significant trading trends.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved to -$12.79M (up 24.59% YoY), and EPS improved to -0.45 (up 12.50% YoY). However, the company is still unprofitable, and gross margin remains at 0%.
Morgan Stanley downgraded the stock to Equal Weight from Overweight with a reduced price target of $14 (down from $23). Analysts cite disappointing Phase 2 trial results and limited near-term upside due to delayed Phase 3 trials.
